Case Report
The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes
Table 2
Clinical characteristics and renal survival of three RA patients with IgA glomerulonephritis following kidney biopsy.
| | Case 1 | Case 2 | Case 3 | | METS-C score | M1, E0, S1, T2, C0 | M1, E1, S1, T2, C0 | M1, E1, S1, T2, C0 |
| | Therapy after kidney biopsy | | Steroids in months | 24 | 24 | 24 | | Methotrexate in months | — | — | 24 | | Original TNF-α inhibitor in months | 24 | 19 | — | | Rituximab (number of cycles) | 3 | 3 | 4 | | Endoxan/Azathioprine | No | Yes | No | | DAS28 one year after biopsy | 3.08 | 2.76 | 4.54 |
| | Renal survival after biopsy | 2 years | 1 year | 1 year | | 24 h urine proteinuria (g/dU) | 2.26 | 3.00 | 0.68 | | Serum creatinine (μmol/L) | 195 | 103 | 88 | | eGFR (mL/min/1.73 m2) | 35.3 | 60.2 | 61.1 |
| | Renal survival after biopsy | 4 years | 2 years | 2 years | | 24 h urine proteinuria (g/dU) | 1.57 | 0.09 | 0.13 | | Serum creatinine (μmol/L) | 166 | 87 | 83 | | eGFR (mL/min/1.73 m2) | 42.2 | 73.3 | 65.1 |
|
|
eGFR-estimated glomerular filtration rate.
|
